INTRODUCTION
Achieving and maintaining high levels of HIV testing among people most at risk of HIV infection is a key goal for HIV prevention programs. Regular HIV testing aims to reduce the time between infection and diagnosis and the number of people with undiagnosed HIV, through earlier diagnosis after infection.1 In Australia and other countries with concentrated HIV epidemics, gay and bisexual men (GBM) with undiagnosed HIV contribute disproportionately to HIV transmission.2–4 Confirming people's knowledge of their HIV status is a fundamental first step for accessing biomedical HIV prevention strategies such as pre-exposure prophylaxis (PrEP) for HIV-negative people and treatment as prevention for people living with HIV.5–7 Timely diagnosis after HIV infection also allows people to benefit from early initiation of HIV treatment, reducing mortality and morbidity.8
Methods for estimating the proportion of undiagnosed HIV include biological prevalence surveys in key populations9 and back-projection methods using CD4 count at diagnosis among people diagnosed with HIV combined with estimates of the size of subpopulations of people living with HIV.10 Bio-behavioral surveillance combines behavioral data and biological samples for HIV testing to calculate prevalence estimates for diagnosed and undiagnosed HIV infection and assess the characteristics of people with undiagnosed infection.11 Repeated bio-behavioral surveillance studies can help to measure the impact of HIV prevention programs over time.11 However, because of the resources required for such studies, very few jurisdictions have conducted bio-behavioral studies over multiple rounds or reported change over time.
Repeated bio-behavioral studies in high-income settings that have collected biological specimens from GBM have reported a wide range in the prevalence of undiagnosed HIV but also declines over time in undiagnosed infection. In Melbourne, Australia, the proportion of undiagnosed HIV among HIV-positive GBM fell from 31.1% in 2008 to 7.1% in 2014.12,13 In San Francisco, United States, the proportion undiagnosed fell from 21.7% in 2004, to 18.0% in 2008, and 7.5% in 2011.14 In Edinburgh and Glasgow, Scotland, undiagnosed HIV fell from 41.7% in 2005, to 26.3% in 2008, and then 25.4% in 2011.15 Across 10 serial cross-sectional studies conducted between 2000 and 2013 in London, England, the proportion undiagnosed fell from 34% to 24%.16 To the best of our knowledge, there have been no repeated estimates of undiagnosed HIV in a period where HIV biomedical prevention strategies such as PrEP have been introduced and scaled up.
In New South Wales (NSW), Australia, state-wide HIV strategies since 2012 have focused on reducing undiagnosed HIV infections through increasing the frequency of HIV testing in priority populations. There have also been initiatives to increase the proportion of people diagnosed with HIV on treatment and to offer PrEP to people at high risk of HIV.17,18 In 2014, we implemented a cross-sectional bio-behavioral surveillance study among GBM in Sydney, NSW, as part of a national study.12 In 2018, we repeated this study to assess changes in the prevalence of undiagnosed HIV among GBM in NSW and characteristics of men with undiagnosed HIV, as part of the evaluation of the NSW HIV Strategies.
METHODS
Participants and Procedures
In February 2014 and February 2018, participants were recruited through the Sydney Gay Community Periodic Survey (SGCPS), an annual behavioral surveillance study.19,20 Trained staff recruited participants at bars and sex-on-premises venues and at the Sydney Gay and Lesbian Mardi Gras Fair Day (hereafter Fair Day), a large community event. Eligible participants were men aged 18 and older who reported regular participation in the Sydney gay community, sex with male partners in the past 5 years, and/or identified as gay or bisexual. Consenting participants self-completed a questionnaire. The Gay Community Periodic Surveys methods and the methods of the 2014 study have been described elsewhere.12,19,20
Men who completed a SGCPS questionnaire were eligible to participate in an additional study (community-based study of undiagnosed HIV and testing or COUNT) to measure HIV prevalence. COUNT recruitment took place at most SGCPS recruitment locations, but clinics, gyms, and online recruitments were excluded. Participants were asked to provide additional consent and a biological sample for HIV testing. Participants could elect to participate anonymously, in which case their test result would not be provided or, confidentially, in which case they agreed to be contacted and receive their result. Oral fluid samples were collected using the OraSure Oral Specimen Collection Device. To match behavioral data with biological specimens, recruiters labeled questionnaires and specimens with unique identifiers and participants' dates of birth. To enable delivery of test results to confidential participants, their consent forms including contact details were also labeled.
Oral fluid samples were sent to the National Serology Reference Laboratory. Samples were tested using an anti-HIV-1 IgG antibody capture enzyme-linked immunosorbent assay.21 Samples that were reactive or indeterminate were repeat tested and reactive results confirmed by Western blot. Consent forms, test results, and questionnaires were sent to the Centre for Social Research in Health at UNSW, Sydney, for data processing and storage.
Study staff trained in HIV test discussions provided results to participants. Where the laboratory test result was concordant with the participant's reported HIV status, a notification was sent by mobile phone text message or email. Participants who reported that they were HIV-negative or untested/unknown and received a nonreactive result were notified that their result was “negative” and provided a link to a secure website, which contained further information about the study, the test result, details of the test window period, and contacts for clinical and support services. Participants who reported that they had previously been diagnosed with HIV and whose test results were reactive were sent a message saying that their results were “positive” and a link to the secure website. For these men, the website contained information about the study, the test result, and contacts for clinical and support services. For these 2 groups of men, the notification text message or email did not mention HIV to protect confidentiality. Participants whose test results were invalid or whose results were reactive, suggesting undiagnosed HIV, were sent a text message asking them to call the study telephone line. If they did not call within 48 hours, they were called repeatedly until contacted. Trained staff handled all calls, provided support, and facilitated appointments for confirmatory serology at local clinics.
The COUNT study was approved by the Ethics Committees of UNSW Sydney and the community-based organization ACON.
Measures
To describe the sample, we assessed sociodemographic characteristics, sexual practices with men in the previous 6 months, recent HIV and sexual health testing history, and drug use. Details of these measures have been published elsewhere.20 Participants were classified as living in “gay Sydney” if they reported living in 1 of 7 postcodes in inner Sydney that have been identified as having a high proportion of gay male residents.22 The primary outcome variable was the participant's HIV status, constructed from self-reported HIV status and laboratory test results (HIV-negative, previously diagnosed HIV-positive, or previously undiagnosed HIV-positive). Test results were matched with participants' self-reported HIV status from questionnaires, and any discrepancies resolved by referring to other questionnaire items (year of HIV diagnosis, HIV treatment status, attending HIV care, viral load, and CD4 count), or by contacting participants (if they had consented to contact).
Data Analysis
Chi-squared tests were used to compare the characteristics of the samples recruited in each round. We calculated the prevalence of HIV and undiagnosed infection and 95% confidence intervals (CIs). To adjust for potential differences in HIV prevalence by recruitment source over time, we calculated adjusted prevalence estimates by weighting prevalence results by the recruitment venue. The weighting method used was to multiply the observed frequencies recruited from each recruitment location type (community event, social venue, and sex venue) by the inverse of the proportion recruited at each location type. The prevalence estimates (proportions) were then recalculated for the adjusted (weighted) sample and applied to the observed sample size, so that the estimated number of cases and 95% confidence intervals could be calculated. Two sample tests of proportion were used to compare the prevalence estimates in 2014 and 2018. Because of the small number of undiagnosed cases, we describe the characteristics of the undiagnosed cases in 2018 and did not compare them with previously diagnosed men or HIV-negative and untested men.
RESULTS
Of the 2222 men recruited face-to-face in the SGCPS in 2014 and the 2158 recruited in 2018, the proportion who participated in the COUNT study was 42.5% (n = 944) in 2014 and 41.2% (n = 890) in 2018. If we limit this to recruitment locations where COUNT recruitment took place (ie, locations such as clinics and gyms were excluded from COUNT), the proportion of SGCPS participants who took part in COUNT was 55.0% in 2014 (944/1715) and 50.6% in 2018 (890/1758). The characteristics of COUNT participants are shown in Table 1. A greater proportion of participants were recruited from social venues (bars) in 2018 than in 2014, and in 2018, more participants chose to participate anonymously (and not receive their test result). In 2018, anonymous participation was strongly correlated with PrEP use. PrEP users (n = 107/179, 59.4%) were more likely than other non–HIV-positive men (n = 196/662, 29.4%) to participate anonymously and not receive their test results (χ2 = 50.65, P < 0.001). The mean age of the samples was similar in 2014 and 2018, as were levels of education and full-time employment and the proportions who identified as gay or resided in “gay Sydney” postcodes.22 Compared with 2014, in 2018 fewer men identified as Anglo-Australian and a higher proportion were born overseas, particularly from Central and South America.
TABLE 1. -
Characteristics of Participants in 2014 and 2018
|
2014, N = 944, n (%) |
2018, N = 890, n (%) |
χ2
|
P
|
Recruitment location |
|
|
31.03 |
<0.001 |
Fair Day |
445 (47.1) |
308 (34.7) |
|
|
Social venue |
398 (42.2) |
480 (53.9) |
|
|
Sex venue |
101 (10.7) |
102 (11.5) |
|
|
Recruitment arm |
|
|
26.70 |
<0.001 |
Anonymous |
253 (26.8) |
339 (38.1) |
|
|
Confidential |
691 (73.2) |
551 (61.9) |
|
|
Self-reported HIV status |
|
|
1.83 |
0.34 |
HIV negative |
778 (82.4) |
753 (84.6) |
|
|
Untested/unknown |
107 (11.2) |
92 (10.3) |
|
|
HIV positive |
59 (6.2) |
45 (5.1) |
|
|
Mean age in years (SD) |
34.4 (11.2) |
35.2 (11.0) |
|
0.12 |
Anglo-Australian |
594 (62.9) |
504 (56.6) |
7.55 |
0.006 |
Born in Australia |
595 (63.0) |
514 (57.8) |
5.33 |
0.021 |
Born overseas |
346 (36.6) |
370 (41.6) |
|
|
Overseas region of birth |
|
|
|
|
High income, English-speaking country |
137 (14.5) |
139 (15.6) |
0.43 |
0.51 |
Europe, non–English-speaking country |
53 (5.6) |
52 (5.8) |
0.04 |
0.83 |
Asia |
96 (10.2) |
102 (11.5) |
0.79 |
0.37 |
Central/South America |
14 (1.5) |
30 (3.4) |
6.97 |
0.009 |
Others |
46 (4.8) |
47 (5.3) |
0.15 |
0.41 |
University degree |
543 (57.5) |
549 (61.7) |
3.29 |
0.07 |
Full-time employed |
759 (80.4) |
718 (80.7) |
0.02 |
0.88 |
Gay-identified |
838 (88.8) |
787 (88.4) |
0.05 |
0.82 |
Resides in “gay Sydney”* |
315 (33.4) |
292 (32.8) |
0.06 |
0.80 |
Resides in rest of Sydney |
629 (66.6) |
598 (67.2) |
|
|
HIV Test in the past 6 months |
468 (49.6) |
501 (56.3) |
8.29 |
0.004 |
Any STI test in the past 12 months (excluding blood test) |
582 (61.7) |
616 (69.2) |
11.56 |
0.001 |
Any STI diagnosis in the past 12 months |
136 (14.4) |
245 (27.5) |
47.92 |
<0.001 |
PEP use in the past 6 months |
39 (4.9) |
44 (4.9) |
0.70 |
0.40 |
PrEP use in the past 6 months (prescribed) |
16 (2.1) |
173 (23.0) |
154.73 |
<0.001 |
How men met their partners in the past 6 months |
|
|
|
|
Internet |
332 (35.2) |
290 (32.5) |
1.36 |
0.24 |
Mobile app |
433 (45.9) |
475 (53.4) |
10.31 |
0.001 |
Gay bar |
295 (31.3) |
280 (31.5) |
0.01 |
0.92 |
Sex venue |
300 (31.8) |
303 (34.0) |
1.06 |
0.30 |
More than 10 male partners the past 6 months |
210 (22.3) |
246 (27.7) |
7.13 |
0.008 |
Any condomless sex with regular partners in the past 6 months |
377 (39.9) |
397 (44.6) |
4.09 |
0.043 |
Any condomless sex with casual partners in the past 6 months |
226 (23.9) |
332 (37.3) |
38.6 |
<0.001 |
Any group sex in the past 6 months |
310 (32.8) |
336 (37.8) |
4.84 |
0.028 |
Used party drugs for sex in the past 6 months |
236 (25.0) |
201 (22.6) |
1.33 |
0.25 |
Any injecting in the past 6 months |
49 (5.2) |
25 (2.8) |
6.71 |
0.01 |
Drugs used in the past 6 months |
|
|
|
|
Amyl nitrite |
414 (43.9) |
437 (49.1) |
5.06 |
0.024 |
Cannabis |
316 (33.5) |
292 (32.8) |
0.09 |
0.76 |
Crystal methamphetamine |
128 (13.6) |
97 (10.9) |
3.01 |
0.08 |
Ecstasy |
284 (30.1) |
256 (28.8) |
0.38 |
0.54 |
Erectile dysfunction medication |
188 (19.9) |
191 (21.5) |
0.66 |
0.41 |
Gamma hydroxybutyrate |
104 (11.0) |
121 (13.6) |
2.82 |
0.09 |
Ketamine |
66 (7.0) |
114 (12.8) |
17.51 |
<0.001 |
*“Gay Sydney” refers to a set of 7 post codes in inner Sydney which have previously been identified as having a high proportion of gay male residents.
Compared with 2014, in 2018, the proportion of men who had been tested for HIV in the previous 6 months and for sexually transmitted infections (STIs) in the previous 12 months (excluding blood tests) increased significantly (from 49.6% to 56.3%, P = 0.004 and from 61.7% to 69.2%, P < 0.001, respectively) (Table 1). There was also a significant increase in the proportion of men who had been diagnosed with any STI in the past 12 months (from 14.4% to 27.5%, P = 0.001). Similar proportions had recently taken postexposure prophylaxis for HIV, but there was a large and significant increase in the proportion of men who had taken PrEP in 2018 (from 2.1% in 2014 to 23.0% in 2018, P < 0.001). In 2018, significantly higher proportions of men reported having met male sex partners through mobile apps (45.9%–53.4%, P = 0.001), having more than 10 male sex partners in the past 6 months (22.3%–27.7%, P = 0.008), having had recent condomless sex with regular or casual partners (39.9%–44.6%, P = 0.043 and 23.9%–37.3%, P < 0.001, respectively), and recently participating in group sex (32.8%–37.8%, P = 0.028).
In 2014 and 2018, similar proportions of men reported the use of party drugs for sex (Table 1) and the use of cannabis, crystal methamphetamine, ecstasy, gamma hydroxybutyrate, and erectile dysfunction medication. In 2018, a lower proportion of men reported recent injecting, but more use of amyl nitrite and ketamine was reported.
Prevalence Estimates of HIV and Undiagnosed Infection
Estimates for HIV and undiagnosed infection prevalence are shown in Table 2. HIV prevalence based on biological testing was 6.9% (65 of 944) in 2014 and 5.5% (49 of 890) in 2018. Among men who were confirmed as HIV-positive by testing, 7 tested HIV-positive and were classified as previously undiagnosed in 2014 (10.8%; 95% CI: 3.2 to 18.3) and 4 tested HIV-positive in 2018 (8.2% 95% CI: 0.5 to 15.8). As a proportion of men who reported that they were HIV-negative or untested at the time of recruitment, undiagnosed men represented 0.8% (95% CI: 0.2% to 1.4%) in 2014 and 0.4% (95% CI: 0.0% to 0.9%) in 2018. There were no statistical differences between the prevalence estimates in 2014 and 2018.
TABLE 2. -
Prevalence Estimates of HIV and Undiagnosed Infection (Unadjusted)
|
COUNT 2014, N = 944, n (%) |
95% CI for % |
COUNT 2018, N = 890, n (%) |
95% CI for % |
P* |
HIV negative (confirmed by testing) |
879/944 (93.1) |
91.5 to 94.7 |
841/890 (94.5) |
93.0 to 96.0 |
0.22 |
HIV positive (confirmed by testing) |
65/944 (6.9) |
5.3 to 8.5 |
49/890 (5.5) |
4.0 to 7.0 |
0.22 |
Previously diagnosed |
58/944 (6.1) |
4.6 to 7.7 |
45/890 (5.0) |
3.6 to 6.5 |
0.31 |
Previously undiagnosed |
7/944 (0.7) |
0.2 to 1.2 |
4/890 (0.4) |
0.0 to 0.9 |
0.42 |
Undiagnosed HIV as a proportion of |
|
|
|
|
|
All HIV-positive participants (confirmed by testing) |
7/65 (10.8) |
3.2 to 18.3 |
4/49 (8.2) |
0.5 to 15.8 |
0.64 |
HIV negative and untested participants (self-reported) |
7/886 (0.8) |
0.2 to 1.4 |
4/845 (0.4) |
0.0 to 0.9 |
0.41 |
*Two-sample test of proportions.
We weighted the samples to adjust for differences in the numbers of participants recruited from different recruitment locations in each round (Table 3). After this adjustment, HIV prevalence was similar in each year (6.1% in 2014 and 6.4% in 2018). In the adjusted analysis, undiagnosed HIV as a proportion of all HIV-positive cases was 13.8% (95% CI: 5.0 to 22.7) in 2014 and 5.3% (95% CI: 0.5 to 11.1) in 2018 (P = 0.12). As a proportion of all HIV-negative and untested men, undiagnosed HIV was 0.9% (95% CI: 0.3 to 1.5) and 0.4% (95% CI: 0.0 to 0.8) in 2014 and 2018, respectively, in the adjusted analysis (P = 0.16).
TABLE 3. -
Adjusted Prevalence Estimates of HIV and Undiagnosed Infection (Weighted by Recruitment Location)
|
COUNT 2014, N = 944, % |
95% CI for % |
COUNT 2018, N = 890, % |
95% CI for % |
P* |
HIV negative (confirmed by testing) |
93.9 |
92.3 to 95.3 |
93.6 |
91.9 to 95.2 |
0.81 |
HIV positive (confirmed by testing) |
6.1 |
4.6 to 7.6 |
6.4 |
4.8 to 8.0 |
0.82 |
Previously diagnosed |
5.3 |
3.8 to 6.7 |
6.1 |
4.5 to 7.6 |
0.48 |
Previously undiagnosed |
0.8 |
0.3 to 1.4 |
0.3 |
0.0 to 0.7 |
0.16 |
Undiagnosed HIV as a proportion of |
|
|
|
|
|
All HIV-positive participants (confirmed by testing) |
13.8 |
5.0 to 22.7 |
5.3 |
0.5 to 11.1 |
0.12 |
HIV negative and untested participants (self-reported) |
0.9 |
0.3 to 1.5 |
0.4 |
0.0 to 0.8 |
0.16 |
*Two-sample test of proportions.
Characteristics of Men With Undiagnosed HIV in 2018
Because of the small number of undiagnosed men, it was not possible to statistically analyze the factors associated with undiagnosed infection. The 4 men who had undiagnosed HIV in 2018 ranged in age between 28 and 37 years. One was born in Australia, 2 were born in other high-income English-speaking countries, and 1 was born in South America. All 4 men identified as gay, but only 1 lived in a “gay Sydney” postcode. Three men were recruited from bars and 1 at a community event. All 4 men reported having been tested for HIV within the previous 6 months and having at least 2 HIV tests in the previous 12 months. Two of the previously undiagnosed men reported no condomless anal intercourse with casual or regular partners in the previous 6 months, but all 4 men reported having participated in group sex at least once in the previous 6 months. Two men reported having been diagnosed with a sexually transmitted infection in the previous 12 months. Two men reported using crystal methamphetamine, ecstasy, or gamma hydroxybutyrate in the past 6 months. One man reported using PrEP in the previous 6 months.
DISCUSSION
In 2014–2018, the prevalence of undiagnosed HIV infection among GBM in Sydney remained low, but the apparent decline in undiagnosed infection was not statistically significant. Based on weighted estimates used to adjust for recruitment variation between rounds, the prevalence of undiagnosed infection among HIV-positive men was 13.8% in 2014 and 5.3% in 2018. Our estimate of undiagnosed HIV infection among HIV-positive GBM in NSW (5.3%) in 2018 is similar to the results of a recent study using the back-projection method of CD4 count at diagnosis that estimated that 8.4% of HIV-positive GBM in NSW were undiagnosed in 2016.23
HIV prevention initiatives in NSW are very likely to have contributed to the low prevalence of undiagnosed HIV among GBM, despite increases in condomless sex and STI diagnoses. The NSW HIV Strategies have prioritized increased HIV testing, earlier initiation of antiretroviral therapy, and the rapid scale-up of PrEP among high-risk GBM.17,18 New peer-led rapid HIV testing services and express HIV testing services at sexual health clinics have attracted high proportions of GBM clients who have never previously tested or who had tested infrequently before.24 In 2016, NSW met the UNAIDS 90-90-90 goals for HIV diagnosis and treatment.23 Between 2014 and 2018, HIV testing frequency among GBM increased, time to HIV treatment decreased, and the level of PrEP use among non–HIV-positive men increased dramatically.25,26 All of these factors are likely to have contributed to the low prevalence of undiagnosed HIV.
Although we could not conduct a detailed analysis of factors associated with undiagnosed infection in 2018, 3 of the 4 men with undiagnosed infection were born overseas. Three lived outside gay Sydney, all were recently tested, suggesting that they had acquired their infections recently, and 3 had not recently used PrEP. Two had recently been diagnosed with syphilis. This echoes HIV epidemiology in NSW which has shown increases in HIV diagnoses among overseas-born GBM, declines in HIV in “gay Sydney” but not elsewhere (most likely because of differential uptake of PrEP), and that recent STI diagnoses remain an indicator of risk for HIV infection among GBM not using PrEP.27
Australian HIV testing guidelines published in 2014 recommended annual HIV testing for all sexually active GBM and 3–6 monthly testing among men with higher risk.28 All 4 of the undiagnosed men in the 2018 study reported that their last HIV test was within the previous 6 months, so they appeared to be testing at the frequency recommended in HIV testing guidelines, and 3 of the 4 reported behavior or a history of STI diagnoses that would place them in the higher risk category in the testing guidelines. Although the average annual number of HIV tests among high-risk men attending clinics in NSW has increased in recent years,27 until 2018 these data included GBM on PrEP, who must test frequently as part of PrEP monitoring. From mid-2018, reporting of these data in NSW has been stratified by PrEP use.27 This new method of reporting revealed that while testing frequency has increased among men on PrEP, there had been no increase in HIV testing among high-risk GBM who are not on PrEP.27 A recent analysis of behavioral surveillance data from Australian GBM also found that while HIV testing frequency among PrEP users had increased between 2013 and 2018, there was no increase among high-risk men not on PrEP.29 Collectively, these findings suggest a need to target effective prevention methods to high-risk GBM who are not on PrEP. Targeted interventions to support men to remain on PrEP or reinitiate use of PrEP at times of increased risk are also needed.
There are some limitations to consider regarding our study. The prevalence of HIV confirmed by testing in our study was 6.2% in 2014 and 5.1% in 2018, well below the self-reported rates in the corresponding SGCPS samples each year, which were 12.9% and 9.1%, respectively.26 This indicates that in both rounds, previously diagnosed HIV-positive men were less likely to participate in the prevalence study than other GBM. In addition, increases in HIV testing and PrEP use between 2014 and 2018 created difficulties in recruiting GBM in the 2018 study. Although our recruiters explained to potential participants that the aim of the study was to measure HIV prevalence among all GBM, men who were on PrEP or who had recently tested for HIV sometimes commented that they saw little benefit in participating in the study (or felt that they would be wasting study resources). Ultimately, the proportion of SGCPS participants who were approached and took part in COUNT in 2014 and 2018 was 50–55%, which may have introduced sampling bias. Because of differences in recruitment between the 2014 and 2018 studies, we developed a weighted sample to account for differences in the proportion of men recruited from different recruitment locations. After weighting, the HIV prevalence in 2014 and 2018 appeared similar, and there was no notable change in our estimate of undiagnosed HIV. International guidelines suggest that bio-behavioral prevalence studies should only be conducted in populations with the “highest HIV prevalence,” with a minimum sample size of 500.30 In the context of falling HIV diagnoses among Australian-born GBM in NSW and the extremely low prevalence of undiagnosed HIV, we have observed it is likely to become more difficult to document any further decline in undiagnosed HIV prevalence through this type of study. Our study was conducted as part of an ongoing program of behavioral HIV surveillance, and given the achievable sample size and low prevalence of undiagnosed HIV in 2014, it had limited statistical power to identify changes in the prevalence of undiagnosed infection in 2018. Recruiting the substantially larger samples required to achieve satisfactory statistical power is likely to be unfeasible. A suggestion for future studies could be the targeted assessment of risk factors and undiagnosed HIV infection among overseas-born GBM, among whom HIV notifications in Australia have not fallen.31
CONCLUSIONS
Based on the results of repeated bio-behavioral surveillance among GBM in Sydney in 2014 and 2018, we found that the prevalence of undiagnosed HIV infections remained low. High levels of HIV testing, treatment, and PrEP use seem to have contributed to a sustained low prevalence of undiagnosed HIV among GBM in NSW.
ACKNOWLEDGMENTS
The authors thank all the gay and bisexual men who participated in these studies and the study recruiters; Dr. Kim Wilson of the National Serology Reference Laboratory for the testing of samples; Caitlin Bambridge of ACON for organizing recruitment; Trevor Dougherty for assistance with recruitment; Rebecca Houghton of Sydney Sexual Health Centre for training in delivery of HIV test results; the Sydney Sexual Health Centre for confirmatory testing of previously undiagnosed men; Drs. Naveed Noor and Christopher Tumwine for assistance with data entry; Johann Kolstee and Philip Cunningham who participated in the COUNT study reference group and the Gay Community Periodic Survey research team.
APPENDIX 1 NSW HIV Prevention Partnership Project Investigators
The investigators on the NSW HIV Prevention Partnership Project Study are Professor Andrew Grulich, Dr. Christine Selvey, Professor Rebecca Guy, Associate Professor Garrett Prestage, Associate Professor Iryna Zablotska, Jo Holden, Tim Duck, Craig Cooper, Karen Price, Professor Martin Holt, Professor John de Wit, Professor John Kaldor, Professor Anthony Kelleher, and Professor David Wilson. The late Alan Brotherton, the late Professor David A. Cooper, and the late Adjunct Associate Professor Levinia Crooks were also investigators on the grant. The project steering committee included these investigators and Bill Whittaker, Phillip Keen, Dr. Denton Callander, Daniel Madeddu, Dr. Heather-Marie Schmidt, Barbara Telfer, Karen Price, Dr. Mark Boyd, Dr. Benjamin R. Bavinton, Scott McGill, Dr. Prital Patel, Cherie Power, Dr. Angie Pinto, Dr. Steven Nigro, Tina Gordon, Lance Feeney, Carolyn Murray, Jane Costello, and ToveLysa Fitzgerald.
REFERENCES
1. Phillips AN, Cambiano V, Miners A, et al. Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. AIDS. 2015;29:1855–1862.
2. Gray RT, Wilson DP, Guy RJ, et al. Undiagnosed HIV infections among gay and bisexual men increasingly contribute to new infections in Australia. J Int AIDS Soc. 2018;21:e25104.
3. Phillips AN, Cambiano V, Nakagawa F, et al. Increased HIV incidence in
men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS One 2013;8:e55312.
4. Ratmann O, Van Sighem A, Bezemer D, et al. Sources of HIV infection among men having sex with men and implications for prevention. Sci Transl Med. 2016;8:320ra2-ra2.
5. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in
men who have sex with men. N Engl J Med. 2010;363:2587–2599.
6. Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237–2246.
7. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.
8. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807.
9. Working Group on Estimation of
HIV Prevalence in Europe. HIV in hiding: methods and data requirements for the estimation of the number of people living with undiagnosed HIV. AIDS. 2011;25:1017–1023.
10. Jansson J, Kerr CC, Mallitt KA, et al. Inferring HIV incidence from case surveillance with CD4+ cell counts. AIDS. 2015;29:1517–1525.
11. Rehle T, Lazzari S, Dallabetta G, et al. Second-generation HIV surveillance: better data for decision-making. Bull World Health Organ. 2004;82:121–127.
12. Holt M, Lea T, Asselin J, et al. The prevalence and correlates of undiagnosed HIV among Australian gay and bisexual men: results of a national, community-based, bio-behavioural survey. J Int AIDS Soc. 2015;18:20526.
13. Stoove M, Asselin J, Pedrana A, et al. Declining prevalence of undiagnosed HIV in Melbourne: results from community-based bio-behavioural studies of gay and bisexual men. Aust N Z J Public Health. 2018;42:57–61.
14. Raymond HF, Chen YH, Ick T, et al. A new trend in the HIV epidemic among
men who have sex with men, San Francisco, 2004-2011. J Acquir Immune Defic Syndr. 2013;62:584–589.
15. Wallace LA, Li J, McDaid LM.
HIV prevalence and undiagnosed infection among a community sample of gay and bisexual men in Scotland, 2005–2011: implications for HIV testing policy and prevention. PLoS One. 2014;9.
16. Aghaizu A, Wayal S, Nardone A, et al. Sexual behaviours, HIV testing, and the proportion of men at risk of transmitting and acquiring HIV in London, UK, 2000-13: a serial cross-sectional study. Lancet HIV 2016;3:e431–e440.
17. NSW Centre for Population Health. NSW HIV Strategy 2012–2015: A New Era. Sydney, Australia: NSW Ministry of Health; 2012.
18. NSW Ministry of Health. NSW HIV Strategy 2016–2020. Sydney, Australia: NSW Ministry of Health, 2015.
19. Holt M, Lea T, Mao L, et al. Adapting behavioural surveillance to antiretroviral-based HIV prevention: reviewing and anticipating trends in the Australian Gay Community Periodic Surveys. Sex Health. 2017;14:72–79.
20. Zablotska IB, Kippax S, Grulich A, et al. Behavioural surveillance among gay men in Australia: methods, findings and policy implications for the prevention of HIV and other sexually transmissible infections. Sex Health. 2011;8:272–279.
21. Parry J, Perry K, Mortimer P. Sensitive assays for viral antibodies in saliva: an alternative to tests on serum. Lancet. 1987;330:72–75.
22. Poynten IM, Stein AN, Conway EL, et al. Geographical clustering of anal cancer incidence in Australia. Sex Health. 2012;9:509–512.
23. Keen P, Gray RT, Telfer B, et al. The 2016 HIV diagnosis and care cascade in New South Wales, Australia: meeting the UNAIDS 90-90-90 targets. J Int AIDS Soc. 2018;21:e25109.
24. Knight V, Wand H, Gray J, et al. Implementation and operational research: convenient HIV testing service models are attracting previously untested gay and bisexual men: a cross-sectional study. J Acquir Immune Defic Syndr. 2015;69:e147–55.
25. NSW Ministry of Health. NSW HIV Strategy 2016–2020 Quarter 4 & Annual 2017 Data Report. Sydney, Australia: NSW Ministry of Health, 2018.
26. Broady T, Mao L, Lee E, et al. Gay Community Periodic Survey: Sydney 2018. Sydney, Australia: Centre for Social Research in Health, UNSW Sydney; 2018.
27. NSW Ministry of Health. NSW HIV Strategy 2016–2020 Quarter 4 & Annual 2018 Data Report. Sydney, Australia: NSW Ministry of Health, 2019.
28. Templeton DJ, Read P, Varma R, et al. Australian sexually transmissible infection and HIV testing guidelines for asymptomatic
men who have sex with men 2014: a review of the evidence. Sex Health. 2014;11:217–229.
29. Bavinton BR, Grulich AE, Broady T, et al. Increases in HIV testing frequency in Australian gay and bisexual men are concentrated among PrEP users: an analysis of Australian behavioural surveillance data, 2013–2018. AIDS Behav. 2020;24:1–12.
30. WHO, CDC, UNAIDS, FHI 360. Biobehavioral survey guidelines for Populations at Risk for HIV. Geneva, Switzerland: World Health Organization; 2017. Licence: CC BY‐NC‐SA 3.0 IGO.
31. The Kirby Institute. HIV, Viral Hepatitis and Sexually Transmissible Infections in Australia: Annual Surveillance Report 2018. Sydney, Australia: Kirby Institute, UNSW Sydney; 2018.